Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics

Letao Yang; Tae Hyung Kim; Hyeon Yeol Cho; Jeffrey Luo; Jong Min Lee; Sy Tsong Dean Chueng; Yannan Hou; Perry To Tien Yin; Jiyou Han; Jong Hoon Kim; Bong Geun Chung; Jeong Woo Choi; Ki Bum Lee

doi:10.1002/adfm.202006918

Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics

Letao Yang, Tae Hyung Kim, Hyeon Yeol Cho, Jeffrey Luo, Jong Min Lee, Sy Tsong Dean Chueng, Yannan Hou, Perry To Tien Yin, Jiyou Han, Jong Hoon Kim, Bong Geun Chung, Jeong Woo Choi, Ki Bum Lee

Department of Biotechnology

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Nanoparticle-based nucleic acid conjugates (NP-NACs) hold great promise for theragnostic applications. However, several limitations have hindered the realization of their full potential in the clinical treatment of cancer and other diseases. In diagnoses, NP-NACs suffer from low signal-to-noise ratios, while the efficiency of NP-NACs-mediated cancer therapies has been limited by the adaptation of alternative prosurvival pathways in cancer cells. The recent emergence of personalized and precision medicine has outlined the importance of having both accurate diagnosis and efficient therapeutics in a single platform. As such, the controlled assembly of hybrid graphene oxide/gold nanoparticle (Au@GO NP)-based cancer-specific NACs (Au@GO NP-NACs) for multimodal imaging and combined therapeutics is reported. The developed Au@GO NP-NACs show excellent surface-enhanced Raman scattering (SERS)-mediated live-cell cancer detection and multimodal synergistic cancer therapy through the use of photothermal, genetic, and chemotherapeutic strategies. Synergistic and selective killing of cancer cells are then demonstrated using in vitro microfluidic models. Moreover, with the distinctive advantages of the Au@GO NP-NACs for cancer theragnostics, precision cancer treatment through the detection of cancer cells in vivo using SERS followed by efficient ablation of tumors is shown. Therefore, the Au@GO NP-NACs can pave a new road for advanced disease theragnostics.

Original language	English
Article number	2006918
Journal	Advanced Functional Materials
Volume	31
Issue number	5
DOIs	https://doi.org/10.1002/adfm.202006918
Publication status	Published - 2021 Jan 27

Keywords

graphene hybrid nanomaterials
multimodal cancer theragnostics
nanomedicine
nanoparticle-based nucleic acid conjugates
personalized medicine

ASJC Scopus subject areas

Chemistry(all)
Materials Science(all)
Condensed Matter Physics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/adfm.202006918

Cite this

Yang, L., Kim, T. H., Cho, H. Y., Luo, J., Lee, J. M., Chueng, S. T. D., Hou, Y., Yin, P. T. T., Han, J., Kim, J. H., Chung, B. G., Choi, J. W., & Lee, K. B. (2021). Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics. Advanced Functional Materials, 31(5), [2006918]. https://doi.org/10.1002/adfm.202006918

@article{d5cb1a68f0e34446ad0dc72a6f4f5959,

title = "Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics",

abstract = "Nanoparticle-based nucleic acid conjugates (NP-NACs) hold great promise for theragnostic applications. However, several limitations have hindered the realization of their full potential in the clinical treatment of cancer and other diseases. In diagnoses, NP-NACs suffer from low signal-to-noise ratios, while the efficiency of NP-NACs-mediated cancer therapies has been limited by the adaptation of alternative prosurvival pathways in cancer cells. The recent emergence of personalized and precision medicine has outlined the importance of having both accurate diagnosis and efficient therapeutics in a single platform. As such, the controlled assembly of hybrid graphene oxide/gold nanoparticle (Au@GO NP)-based cancer-specific NACs (Au@GO NP-NACs) for multimodal imaging and combined therapeutics is reported. The developed Au@GO NP-NACs show excellent surface-enhanced Raman scattering (SERS)-mediated live-cell cancer detection and multimodal synergistic cancer therapy through the use of photothermal, genetic, and chemotherapeutic strategies. Synergistic and selective killing of cancer cells are then demonstrated using in vitro microfluidic models. Moreover, with the distinctive advantages of the Au@GO NP-NACs for cancer theragnostics, precision cancer treatment through the detection of cancer cells in vivo using SERS followed by efficient ablation of tumors is shown. Therefore, the Au@GO NP-NACs can pave a new road for advanced disease theragnostics.",

keywords = "graphene hybrid nanomaterials, multimodal cancer theragnostics, nanomedicine, nanoparticle-based nucleic acid conjugates, personalized medicine",

author = "Letao Yang and Kim, {Tae Hyung} and Cho, {Hyeon Yeol} and Jeffrey Luo and Lee, {Jong Min} and Chueng, {Sy Tsong Dean} and Yannan Hou and Yin, {Perry To Tien} and Jiyou Han and Kim, {Jong Hoon} and Chung, {Bong Geun} and Choi, {Jeong Woo} and Lee, {Ki Bum}",

note = "Funding Information: This work was partially supported by NSF (No. CHE‐1429062, CBET‐1803517), the New Jersey Commission on Spinal Cord Research (Nos. CSCR17IRG010 and CSCR16ERG019), NIH R21 (No. R21AR071101), and NIH R01 (Nos. 1R01DC016612, 3R01DC016612‐01S1, and 5R01DC016612‐02S1). All animals were acclimatized to the animal facility for at least 48 hours before experimentation and maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. The animal protocol was approved by the Institutional review board of the Korea University (protocol number:1040548‐KU‐IRB‐13‐9‐A‐1). Funding Information: This work was partially supported by NSF (No. CHE-1429062, CBET-1803517), the New Jersey Commission on Spinal Cord Research (Nos. CSCR17IRG010 and CSCR16ERG019), NIH R21 (No. R21AR071101), and NIH R01 (Nos. 1R01DC016612, 3R01DC016612-01S1, and 5R01DC016612-02S1). All animals were acclimatized to the animal facility for at least 48 hours before experimentation and maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. The animal protocol was approved by the Institutional review board of the Korea University (protocol number:1040548-KU-IRB-13-9-A-1). Publisher Copyright: {\textcopyright} 2020 Wiley-VCH GmbH",

year = "2021",

month = jan,

day = "27",

doi = "10.1002/adfm.202006918",

language = "English",

volume = "31",

journal = "Advanced Functional Materials",

issn = "1616-301X",

publisher = "Wiley-VCH Verlag",

number = "5",

}

TY - JOUR

T1 - Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics

AU - Yang, Letao

AU - Kim, Tae Hyung

AU - Cho, Hyeon Yeol

AU - Luo, Jeffrey

AU - Lee, Jong Min

AU - Chueng, Sy Tsong Dean

AU - Hou, Yannan

AU - Yin, Perry To Tien

AU - Han, Jiyou

AU - Kim, Jong Hoon

AU - Chung, Bong Geun

AU - Choi, Jeong Woo

AU - Lee, Ki Bum

N1 - Funding Information: This work was partially supported by NSF (No. CHE‐1429062, CBET‐1803517), the New Jersey Commission on Spinal Cord Research (Nos. CSCR17IRG010 and CSCR16ERG019), NIH R21 (No. R21AR071101), and NIH R01 (Nos. 1R01DC016612, 3R01DC016612‐01S1, and 5R01DC016612‐02S1). All animals were acclimatized to the animal facility for at least 48 hours before experimentation and maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. The animal protocol was approved by the Institutional review board of the Korea University (protocol number:1040548‐KU‐IRB‐13‐9‐A‐1). Funding Information: This work was partially supported by NSF (No. CHE-1429062, CBET-1803517), the New Jersey Commission on Spinal Cord Research (Nos. CSCR17IRG010 and CSCR16ERG019), NIH R21 (No. R21AR071101), and NIH R01 (Nos. 1R01DC016612, 3R01DC016612-01S1, and 5R01DC016612-02S1). All animals were acclimatized to the animal facility for at least 48 hours before experimentation and maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. The animal protocol was approved by the Institutional review board of the Korea University (protocol number:1040548-KU-IRB-13-9-A-1). Publisher Copyright: © 2020 Wiley-VCH GmbH

PY - 2021/1/27

Y1 - 2021/1/27

N2 - Nanoparticle-based nucleic acid conjugates (NP-NACs) hold great promise for theragnostic applications. However, several limitations have hindered the realization of their full potential in the clinical treatment of cancer and other diseases. In diagnoses, NP-NACs suffer from low signal-to-noise ratios, while the efficiency of NP-NACs-mediated cancer therapies has been limited by the adaptation of alternative prosurvival pathways in cancer cells. The recent emergence of personalized and precision medicine has outlined the importance of having both accurate diagnosis and efficient therapeutics in a single platform. As such, the controlled assembly of hybrid graphene oxide/gold nanoparticle (Au@GO NP)-based cancer-specific NACs (Au@GO NP-NACs) for multimodal imaging and combined therapeutics is reported. The developed Au@GO NP-NACs show excellent surface-enhanced Raman scattering (SERS)-mediated live-cell cancer detection and multimodal synergistic cancer therapy through the use of photothermal, genetic, and chemotherapeutic strategies. Synergistic and selective killing of cancer cells are then demonstrated using in vitro microfluidic models. Moreover, with the distinctive advantages of the Au@GO NP-NACs for cancer theragnostics, precision cancer treatment through the detection of cancer cells in vivo using SERS followed by efficient ablation of tumors is shown. Therefore, the Au@GO NP-NACs can pave a new road for advanced disease theragnostics.

AB - Nanoparticle-based nucleic acid conjugates (NP-NACs) hold great promise for theragnostic applications. However, several limitations have hindered the realization of their full potential in the clinical treatment of cancer and other diseases. In diagnoses, NP-NACs suffer from low signal-to-noise ratios, while the efficiency of NP-NACs-mediated cancer therapies has been limited by the adaptation of alternative prosurvival pathways in cancer cells. The recent emergence of personalized and precision medicine has outlined the importance of having both accurate diagnosis and efficient therapeutics in a single platform. As such, the controlled assembly of hybrid graphene oxide/gold nanoparticle (Au@GO NP)-based cancer-specific NACs (Au@GO NP-NACs) for multimodal imaging and combined therapeutics is reported. The developed Au@GO NP-NACs show excellent surface-enhanced Raman scattering (SERS)-mediated live-cell cancer detection and multimodal synergistic cancer therapy through the use of photothermal, genetic, and chemotherapeutic strategies. Synergistic and selective killing of cancer cells are then demonstrated using in vitro microfluidic models. Moreover, with the distinctive advantages of the Au@GO NP-NACs for cancer theragnostics, precision cancer treatment through the detection of cancer cells in vivo using SERS followed by efficient ablation of tumors is shown. Therefore, the Au@GO NP-NACs can pave a new road for advanced disease theragnostics.

KW - graphene hybrid nanomaterials

KW - multimodal cancer theragnostics

KW - nanomedicine

KW - nanoparticle-based nucleic acid conjugates

KW - personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=85093511960&partnerID=8YFLogxK

U2 - 10.1002/adfm.202006918

DO - 10.1002/adfm.202006918

M3 - Article

AN - SCOPUS:85093511960

SN - 1616-301X

VL - 31

JO - Advanced Functional Materials

JF - Advanced Functional Materials

IS - 5

M1 - 2006918

ER -

Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this